Eli Lilly's Second 'Game-Changing' Alzheimer's Drug Kisunla™ Approved in UK

Oct 23, 2024, 09:30 AM

Eli Lilly's Alzheimer's treatment, Kisunla™ (donanemab-azbt), has received marketing authorization in Great Britain. The approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) allows the drug to be used for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are Apolipoprotein E Ε4 heterozygotes or non-carriers. This marks a significant development in Alzheimer's treatment options available in the UK. The drug, which trades under the ticker $LLY, is considered the second 'game-changing' Alzheimer's drug to receive approval in the UK.